A Phase 3 interventional study of Guselkumab Dose 1 and Guselkumab Dose 2 in Crohn Disease, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 345 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing guselkumab in Crohn Disease — 6 open to participants now, 11 under way, 7 of them phase 3. guselkumab · Crohn Disease.
Among the 13 studies testing guselkumab in Crohn Disease, this one is the 4th largest by enrollment, is one of 3 that started in 2022, is one of 8 in phase 3, reaches primary completion later than 0 of the 10 other live ones, and was the 3rd registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →6 of the 13 studies testing guselkumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Sites in France
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Austria, Belgium and 14 more countries
Ages 18+
Xian-Janssen Pharmaceutical Ltd. · Sites in China
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Argentina, Australia and 15 more countries
Ages 3+
By country, each count listing its studies:
guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 9 · Phase 4 3
First in 2018; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 350 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 196 across the 13 interventional studies. Of the 2 that completed or were terminated, 2 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 13 have an industry lead sponsor. The 5 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
63 studies in Crohn Disease by Johnson & Johnson: 16 open now, 23 under way, 10 of them phase 3. Of 38 finished, 16 (42%) have results posted.
Among the 63 studies in Crohn Disease by Johnson & Johnson, this one is the 15th largest by enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2022, is one of 23 in phase 3, reaches primary completion later than 0 of the 22 other live ones, and was the 42nd registered.
Johnson & Johnson’s Crohn Disease studies by the year they started, since 1995.
5 of the studies testing guselkumab in Crohn Disease that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT06408935Phase 3Janssen-Cilag Ltd.Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | 2027-06-08 |
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT07654751Janssen Research & Development, LLCA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | 2027-08-31 |
| NCT07310095Xian-Janssen Pharmaceutical Ltd.A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD) | 2027-09-15 |
Add all 5 to your calendar (.ics) → With an account.
Among the 13 studies testing guselkumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 63 in Crohn Disease:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive guselkumab (Dose 1) injection subcutaneously followed by guselkumab (Dose 2) injection subcutaneously.
Drug: Guselkumab Dose 1 · Drug: Guselkumab Dose 2
Participants will receive guselkumab (Dose 1) injection subcutaneously followed by guselkumab (Dose 3) injection subcutaneously.
Drug: Guselkumab Dose 1 · Drug: Guselkumab Dose 3
Participants will receive placebo injection subcutaneously.
Drug: Placebo
Guselkumab (Dose 1) will be administered by subcutaneous (SC) injection.
Guselkumab (Dose 2) will be administered by SC injection.
Guselkumab (Dose 3) will be administered by SC injection.
Placebo will be administered by SC injection.
Percentage of Participants Who Achieved Clinical Remission at Week 12
Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) and a decrease in total CDAI score over time indicates improvement in disease activity.
Time frame: At Week 12
Percentage of Participants Who Achieved Endoscopic Response at Week 12
Percentage of participants who achieved endoscopic response at Week 12 were reported. Endoscopic response was defined as greater than or equal to (\>=) 50 percent (%) improvement from baseline in the Simple Endoscopic Score for Crohn's Disease (SES-CD) score. SES-CD evaluated 4 endoscopic components (presence and size of ulcer, extent of ulcerated surface, extent of affected surface, and presence and type of narrowing) across 5 ileocolonic segments (ileum, right colon, transverse colon, left colon, and rectum), each scored from 0 (best) to 3 (worst) for each segment except narrowing component for which the maximum total score (that is, stricturing) was 11 points. The total SES-CD score was the sum of all the component scores across all the segments and it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.
Time frame: At Week 12
Percentage of Participants Who Achieved Clinical Remission at Week 24
Percentage of participants who achieved clinical remission at Week 24 were reported. Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) and a decrease in total CDAI score over time indicates improvement in disease activity.
Time frame: At Week 24
Percentage of Participants Who Achieved Patient-reported Outcome (PRO)-2 Remission at Week 12
Percentage of participants who achieved PRO-2 remission at Week 12 were reported. PRO-2 remission was defined as an abdominal pain (AP) mean daily score \<=1, and stool frequency (SF) mean daily score \<=3, and no worsening of AP or SF from baseline. Mean daily AP score based on the CDAI was defined as the sum of abdominal pain/cramps ratings in the previous 7 days in a diary card divided by the total number of days assessments were performed. Average daily SF score based on the CDAI was defined as the sum of number of liquid or very soft stools in the previous 7 days in a diary card divided by the total number of days assessments were performed. Mean daily SF and AP scores at a scheduled visit were not calculated if total number of days of assessment was less than 5. Higher PRO-2 scores indicated more severe disease.
Time frame: At Week 12
Percentage of Participants Who Achieved Clinical Response at Week 12
Clinical response was defined as a decrease from baseline in CDAI score \>= 100 points or CDAI score \< 150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) and a decrease in total CDAI score over time indicates improvement in disease activity.
Time frame: At Week 12
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Through Week 48
Percentage of participants with TEAEs through Week 48 were reported. An adverse event (AE) was any untoward medical occurrence in a clinical study participant participating in a clinical study and does not necessarily have a causal relationship with the study drug. An AE that occurred at or after the initial administration of study drug (Week 0) through data cutoff of Week 48 was considered treatment-emergent.
Time frame: Placebo, Guselkumab 400 mg + 100 mg, and Guselkumab 400 mg + 200 mg: From Week 0 up to Week 48; Placebo arm subset - Rescue Treatment: From Week 16 up to Week 48
Percentage of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) Through Week 48
Percentage of participants with TESAEs through Week 48 were reported. An SAE was any untoward medical occurrence in a clinical study participant resulting in any of the following outcomes or was deemed significant for any other reason: death, life-threatening (immediate risk of dying), initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect. An AE does not necessarily have a causal relationship with the study drug. Any SAE that occurred at or after the initial administration of study drug (Week 0) through the data cutoff of Week 48 was considered treatment-emergent.
Time frame: Placebo, Guselkumab 400 mg + 100 mg, and Guselkumab 400 mg + 200 mg: From Week 0 up to Week 48; Placebo arm subset - Rescue Treatment: From Week 16 up to Week 48
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Discontinuation of Study Drug Through Week 48
Percentage of participants with TEAEs leading to discontinuation of study drug through Week 48 were reported. An adverse event (AE) was any untoward medical occurrence in a clinical study participant participating in a clinical study and does not necessarily have a causal relationship with the study drug. An AE that occurred at or after the initial administration of study drug (Week 0) through data cutoff of Week 48 was considered treatment-emergent.
Time frame: Placebo, Guselkumab 400 mg + 100 mg, and Guselkumab 400 mg + 200 mg: From Week 0 up to Week 48; Placebo arm subset - Rescue Treatment: From Week 16 up to Week 48
Out of 350 participants randomized (1:1:1) to 1 of 3 treatments, 3 participants were excluded from all analysis sets due to non-compliance with Good Clinical Practice (GCP) guidance at 1 study site. Hence 347 participants were included in full analysis set. Study included a 24 week (wk) main treatment (12-wk induction followed by 12-wk maintenance) period followed by extension treatment period. In extension period, participants continued same maintenance dose regimen they received at Week 24.
| Milestone | Placebo | Guselkumab 400 mg + 100 mg | Guselkumab 400 mg + 200 mg |
|---|---|---|---|
| Started | 118 | 117 | 115 |
| Treated | 117 | 115 | 115 |
| Participants who met at least 1 rescue criteria at week 16 | 44 | 14 | 14 |
| Completed | 99 | 110 | 114 |
| Not completed | 19 | 7 | 1 |
| Withdrew: Death | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 3 | 1 | 0 |
| Withdrew: Withdrawal by subject | 15 | 3 | 1 |
| Withdrew: Gcp non-compliance | 1 | 2 | 0 |
Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) and a decrease in total CDAI score over time indicates improvement in disease activity.
| Percentage of participants | Placebo | Combined: Guselkumab 400 mg |
|---|---|---|
| Percentage of Participants Who Achieved Clinical Remission at Week 12 | 21.4 (13.9 to 28.8) | 56.1 (49.7 to 62.5) |
Percentage of participants who achieved endoscopic response at Week 12 were reported. Endoscopic response was defined as greater than or equal to (\>=) 50 percent (%) improvement from baseline in the Simple Endoscopic Score for Crohn's Disease (SES-CD) score. SES-CD evaluated 4 endoscopic components (presence and size of ulcer, extent of ulcerated surface, extent of affected surface, and presence and type of narrowing) across 5 ileocolonic segments (ileum, right colon, transverse colon, left colon, and rectum), each scored from 0 (best) to 3 (worst) for each segment except narrowing component for which the maximum total score (that is, stricturing) was 11 points. The total SES-CD score was the sum of all the component scores across all the segments and it ranged from 0 (best) to 56 (worst), where higher scores indicated more severe disease.
| Percentage of participants | Placebo | Combined: Guselkumab 400 mg |
|---|---|---|
| Percentage of Participants Who Achieved Endoscopic Response at Week 12 | 21.4 (13.9 to 28.8) | 41.3 (34.9 to 47.7) |
Percentage of participants who achieved clinical remission at Week 24 were reported. Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) and a decrease in total CDAI score over time indicates improvement in disease activity.
| Percentage of participants | Placebo | Guselkumab 400 mg + 100 mg | Guselkumab 400 mg + 200 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved Clinical Remission at Week 24 | 21.4 (13.9 to 28.8) | 60.9 (51.9 to 69.8) | 58.3 (49.2 to 67.3) |
Percentage of participants who achieved PRO-2 remission at Week 12 were reported. PRO-2 remission was defined as an abdominal pain (AP) mean daily score \<=1, and stool frequency (SF) mean daily score \<=3, and no worsening of AP or SF from baseline. Mean daily AP score based on the CDAI was defined as the sum of abdominal pain/cramps ratings in the previous 7 days in a diary card divided by the total number of days assessments were performed. Average daily SF score based on the CDAI was defined as the sum of number of liquid or very soft stools in the previous 7 days in a diary card divided by the total number of days assessments were performed. Mean daily SF and AP scores at a scheduled visit were not calculated if total number of days of assessment was less than 5. Higher PRO-2 scores indicated more severe disease.
| Percentage of participants | Placebo | Combined: Guselkumab 400 mg |
|---|---|---|
| Percentage of Participants Who Achieved Patient-reported Outcome (PRO)-2 Remission at Week 12 | 17.1 (10.3 to 23.9) | 49.1 (42.7 to 55.6) |
Clinical response was defined as a decrease from baseline in CDAI score \>= 100 points or CDAI score \< 150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary card. The total CDAI score ranged from 0 (improvement in disease activity) to 600 (more disease activity) and a decrease in total CDAI score over time indicates improvement in disease activity.
| Percentage of participants | Placebo | Combined: Guselkumab 400 mg |
|---|---|---|
| Percentage of Participants Who Achieved Clinical Response at Week 12 | 33.3 (24.8 to 41.9) | 73.5 (67.8 to 79.2) |
Percentage of participants with TEAEs through Week 48 were reported. An adverse event (AE) was any untoward medical occurrence in a clinical study participant participating in a clinical study and does not necessarily have a causal relationship with the study drug. An AE that occurred at or after the initial administration of study drug (Week 0) through data cutoff of Week 48 was considered treatment-emergent.
| Percentage of participants | Placebo | Guselkumab 400 mg + 100 mg | Guselkumab 400 mg + 200 mg | Placebo Arm Subset (Rescue Treatment): Placebo to Guselkumab |
|---|---|---|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Through Week 48 | 65.8 | 82.6 | 80.0 | 75.0 |
Percentage of participants with TESAEs through Week 48 were reported. An SAE was any untoward medical occurrence in a clinical study participant resulting in any of the following outcomes or was deemed significant for any other reason: death, life-threatening (immediate risk of dying), initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect. An AE does not necessarily have a causal relationship with the study drug. Any SAE that occurred at or after the initial administration of study drug (Week 0) through the data cutoff of Week 48 was considered treatment-emergent.
| Percentage of participants | Placebo | Guselkumab 400 mg + 100 mg | Guselkumab 400 mg + 200 mg | Placebo Arm Subset (Rescue Treatment): Placebo to Guselkumab |
|---|---|---|---|---|
| Percentage of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) Through Week 48 | 13.7 | 13.0 | 7.8 | 2.3 |
Percentage of participants with TEAEs leading to discontinuation of study drug through Week 48 were reported. An adverse event (AE) was any untoward medical occurrence in a clinical study participant participating in a clinical study and does not necessarily have a causal relationship with the study drug. An AE that occurred at or after the initial administration of study drug (Week 0) through data cutoff of Week 48 was considered treatment-emergent.
| Percentage of participants | Placebo | Guselkumab 400 mg + 100 mg | Guselkumab 400 mg + 200 mg | Placebo Arm Subset (Rescue Treatment): Placebo to Guselkumab |
|---|---|---|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Discontinuation of Study Drug Through Week 48 | 8.5 | 3.5 | 2.6 | 2.3 |
Collected over For arms Placebo, Guselkumab 400 mg + 100 mg, and Guselkumab 400 mg + 200 mg: From Week 0 up to Week 48; Placebo arm subset - Rescue Treatment: From Week 16 up to Week 48. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/117 (0%) | 16/117 (13.7%) | 57/117 (48.7%) |
| Placebo Arm Subset (Rescue Treatment): Placebo to Guselkumab | 0/44 (0%) | 1/44 (2.3%) | 19/44 (43.2%) |
| Guselkumab 400 mg + 100 mg | 1/115 (0.9%) | 15/115 (13%) | 65/115 (56.5%) |
| Guselkumab 400 mg + 200 mg | 0/115 (0%) | 9/115 (7.8%) | 68/115 (59.1%) |
| Event | Placebo | Placebo Arm Subset (Rescue Treatment): Placebo to Guselkumab | Guselkumab 400 mg + 100 mg | Guselkumab 400 mg + 200 mg |
|---|---|---|---|---|
| Crohn's DiseaseGastrointestinal disorders | 7/117 | 0/44 | 1/115 | 1/115 |
| Anal AbscessInfections and infestations | 0/117 | 1/44 | 0/115 | 0/115 |
| IleusGastrointestinal disorders | 0/117 | 0/44 | 2/115 | 0/115 |
| Ventricular TachycardiaCardiac disorders | 0/117 | 0/44 | 0/115 | 1/115 |
| KeratitisEye disorders | 0/117 | 0/44 | 0/115 | 1/115 |
| Abdominal PainGastrointestinal disorders | 0/117 | 0/44 | 1/115 | 0/115 |
| Anal FistulaGastrointestinal disorders | 0/117 | 0/44 | 1/115 | 0/115 |
| GastritisGastrointestinal disorders | 0/117 | 0/44 | 1/115 | 1/115 |
| Pancreatitis AcuteGastrointestinal disorders | 0/117 | 0/44 | 0/115 | 1/115 |
| CholelithiasisHepatobiliary disorders | 0/117 | 0/44 | 0/115 | 1/115 |
| Event | Placebo | Placebo Arm Subset (Rescue Treatment): Placebo to Guselkumab | Guselkumab 400 mg + 100 mg | Guselkumab 400 mg + 200 mg |
|---|---|---|---|---|
| Upper Respiratory Tract InfectionInfections and infestations | 12/117 | 8/44 | 15/115 | 15/115 |
| Crohn's DiseaseGastrointestinal disorders | 17/117 | 3/44 | 8/115 | 5/115 |
| Abdominal PainGastrointestinal disorders | 7/117 | 3/44 | 10/115 | 14/115 |
| Covid-19Infections and infestations | 8/117 | 1/44 | 11/115 | 11/115 |
| HeadacheNervous system disorders | 5/117 | 1/44 | 7/115 | 9/115 |
| AnaemiaBlood and lymphatic system disorders | 3/117 | 0/44 | 8/115 | 2/115 |
| NasopharyngitisInfections and infestations | 6/117 | 3/44 | 8/115 | 0/115 |
| PyrexiaGeneral disorders | 8/117 | 2/44 | 3/115 | 6/115 |
| DiarrhoeaGastrointestinal disorders | 3/117 | 0/44 | 6/115 | 4/115 |
| InfluenzaInfections and infestations | 5/117 | 1/44 | 6/115 | 6/115 |
Baseline characteristics data were presented for full analysis set (FAS) which included all randomized participants who received at least 1 dose of study intervention.
| Age, Categorical(Participants) | Placebo | Guselkumab 400 mg + 100 mg | Guselkumab 400 mg + 200 mg | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 114 | 113 | 111 | 338 |
| >=65 years | 3 | 2 | 4 | 9 |
| Sex: Female, Male(Participants) | Placebo | Guselkumab 400 mg + 100 mg | Guselkumab 400 mg + 200 mg | Total |
|---|---|---|---|---|
| Female | 50 | 49 | 45 | 144 |
| Male | 67 | 66 | 70 | 203 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Guselkumab 400 mg + 100 mg | Guselkumab 400 mg + 200 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 9 | 10 | 8 | 27 |
| Not Hispanic or Latino | 93 | 94 | 98 | 285 |
| Unknown or Not Reported | 15 | 11 | 9 | 35 |
| Race (NIH/OMB)(Participants) | Placebo | Guselkumab 400 mg + 100 mg | Guselkumab 400 mg + 200 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 28 | 26 | 22 | 76 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 0 | 4 | 9 |
| White | 71 | 79 | 79 | 229 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 13 | 10 | 10 | 33 |
| Region of Enrollment(Participants) | Placebo | Guselkumab 400 mg + 100 mg | Guselkumab 400 mg + 200 mg | Total |
|---|---|---|---|---|
| BELGIUM | 1 | 0 | 1 | 2 |
| Bosnia | 3 | 4 | 4 | 11 |
| BRAZIL | 13 | 12 | 7 | 32 |
| CHINA | 19 | 16 | 16 | 51 |
| CROATIA | 0 | 1 | 2 | 3 |
| CZECH REPUBLIC | 5 | 7 | 2 | 14 |
| FRANCE | 5 | 3 | 3 | 11 |
| GERMANY | 4 | 8 | 1 | 13 |
| HUNGARY | 4 | 3 | 3 | 10 |
| ISRAEL | 0 | 0 | 1 | 1 |
| ITALY | 0 | 1 | 1 | 2 |
| JAPAN | 5 | 1 | 0 | 6 |
| JORDAN | 15 | 8 | 9 | 32 |
| LITHUANIA | 1 | 0 | 2 | 3 |
| MALAYSIA | 0 | 1 | 2 | 3 |
| NEW ZEALAND | 0 | 1 | 1 | 2 |
| POLAND | 27 | 28 | 33 | 88 |
| SLOVAKIA | 1 | 4 | 4 | 9 |
| SOUTH KOREA | 2 | 6 | 3 | 11 |
| SPAIN | 1 | 3 | 1 | 5 |
| TAIWAN | 2 | 0 | 1 | 3 |
| TURKEY | 1 | 3 | 1 | 5 |
| UNITED STATES | 8 | 5 | 17 | 30 |
| AgeContinuous(years) | Placebo | Guselkumab 400 mg + 100 mg | Guselkumab 400 mg + 200 mg | Total |
|---|---|---|---|---|
| Mean | 36 ± 12.71 | 37.4 ± 13.32 | 39.1 ± 12.56 | 37.5 ± 12.89 |
Showing the first 100 of 345 sites across 27 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Jan 2022 to primary completion in Jul 2023, 17 months.
Results were first posted in Feb 2025, 1 year 7 months after primary completion. A results delay was requested in Jul 2024.
Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 17 months is below that.
Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Guselkumab
Janssen Research & Development, LLC →